Aleksandar Obradovic

Dr. Aleksandar Obradovic

Medicine, Columbia University Medical Center, New York, USA
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Cell
Verified
Journal Article
Closed access
AOAleksandar Obradovic
Aleksandar Obradovic
NCNivedita Chowdhury
Nivedita Chowdhury
SHScott M. Haake
Scott M. Haake
CACasey Ager
Casey Ager
VWVinson Wang
Vinson Wang
CDCharles G. Drake
Charles G. Drake

19 July 2021 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
ZLZoila A. Lopez-Bujanda
Zoila A. Lopez-Bujanda
MHMichael C. Haffner
Michael C. Haffner
MCMatthew G. Chaimowitz
Matthew G. Chaimowitz
NCNivedita Chowdhury
Nivedita Chowdhury
NVNicholas J. Venturini
Nicholas J. Venturini
CDCharles G. Drake
Charles G. Drake

21 October 2016 in Science Immunology
Verified
Journal Article
Closed access
PDF file
JZJulien Zuber
Julien Zuber
BSBrittany Shonts
Brittany Shonts
SLSai-Ping Lau
Sai-Ping Lau
AOAleksandar Obradovic
Aleksandar Obradovic
JFJianing Fu
Jianing Fu
MSMegan Sykes
Megan Sykes
One paradigm in transplantation is that graft-infiltrating T cells are largely nonalloreactive “bystander” cells. However, the origin and specificity of allograft T cells over time have not been investigated in detail in animals or humans. We used polychromatic flow cytometry and high-throughput T cell receptor sequencing of serial biopsies to show that gut-resident T cell turnover kinetics in human intestinal allografts are correlated with the balance between intragraft host-versus-graft (HvG) and graft-versus-host (GvH) reactivities and with clinical outcomes. In the absence of rejection, donor T cells were enriched for GvH-reactive clones that persisted in the long term in the graft. Early expansion of GvH clones in the graft correlated with the rapid replacement of donor antigen-presenting cells by the recipient. Rejection was associated with transient infiltration by blood-like recipient CD28+ NKG2DHi CD8+ αβ T cells, marked predominance of HvG clones, and accelerated T cell turnover in the graft. Ultimately, these recipient T cells acquired a steady-state tissue-resident phenotype but regained CD28 expression during rejections. Increased ratios of GvH to HvG clones were seen in nonrejectors, potentially mitigating the constant threat of rejection posed by HvG clones persisting within the tissue-resident graft T cell population.

15 March 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AOAleksandar Obradovic
Aleksandar Obradovic
MDMatthew C. Dallos
Matthew C. Dallos
MZMarianna L. Zahurak
Marianna L. Zahurak
APAlan W. Partin
Alan W. Partin
ESEdward M. Schaeffer
Edward M. Schaeffer
CDCharles G. Drake
Charles G. Drake
Purpose: Previous studies suggest that androgen deprivation therapy (ADT) promotes antitumor immunity in prostate cancer. Whether a vaccine-based approach can augment this effect remains unknown. Patients and Methods: We conducted a neoadjuvant, randomized study to quantify the immunologic effects of a GM-CSF–secreting allogeneic cellular vaccine in combination with low-dose cyclophosphamide (Cy/GVAX) followed by degarelix versus degarelix alone in patients with high-risk localized prostate adenocarcinoma who were planned for radical prostatectomy. Results: Both Cy/GVAX plus degarelix and degarelix alone led to significant increases in intratumoral CD8+ T-cell infiltration and PD-L1 expression as compared with a cohort of untreated, matched controls. However, the CD8+ T-cell infiltrate was accompanied by a proportional increase in regulatory T cells (Treg), suggesting that adaptive Treg resistance may dampen the immunogenicity of ADT. Although Cy/GVAX followed by degarelix was associated with a modest improvement in time-to-PSA progression and time-to-next treatment, as well as an increase in PD-L1, there was no difference in the CD8+ T-cell infiltrate as compared with degarelix alone. Gene expression profiling demonstrated that CHIT1, a macrophage marker, was differentially upregulated with Cy/GVAX plus degarelix compared with degarelix alone. Conclusions: Our results highlight that ADT with or without Cy/GVAX induces a complex immune response within the prostate tumor microenvironment. These data have important implications for combining ADT with immunotherapy. In particular, our finding that ADT increases both CD8+ T cells and Tregs supports the development of regimens combining ADT with Treg-depleting agents in the treatment of prostate cancer.

9 August 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
SDSusan DeWolf
Susan DeWolf
BGBoris Grinshpun
Boris Grinshpun
TSThomas Savage
Thomas Savage
SLSai Ping Lau
Sai Ping Lau
AOAleksandar Obradovic
Aleksandar Obradovic
YSYufeng Shen
Yufeng Shen
Alloreactive T lymphocytes are the primary mediators of immune responses in transplantation, both in the graft-versus-host and host-versus-graft directions. While essentially all clones comprising the human T cell repertoire have been selected on self-peptide presented by self–human leukocyte antigens (self-HLAs), much remains to be understood about the nature of clones capable of responding to allo-HLA molecules. Quantitative tools to study these cells are critical to understand fundamental features of this important response; however, the large size and diversity of the alloreactive T cell repertoire in humans presents a great technical challenge. We have developed a high-throughput T cell receptor (TCR) sequencing approach to characterize the human alloresponse. We present a statistical method to model T cell clonal frequency distribution and quantify repertoire diversity. Using these approaches, we measured the diversity and frequency of distinct alloreactive CD4 + and CD8 + T cell populations in HLA-mismatched responder-stimulator pairs. Our findings indicate that the alloimmune repertoire is highly specific for a given pair of individuals, that most alloreactive clones circulate at low frequencies, and that a high proportion of TCRs is likely able to recognize alloantigens.

15 November 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
TSThomas M. Savage
Thomas M. Savage
BSBrittany A. Shonts
Brittany A. Shonts
AOAleksandar Obradovic
Aleksandar Obradovic
SDSusan Dewolf
Susan Dewolf
SLSaiping Lau
Saiping Lau
MSMegan Sykes
Megan Sykes
Allograft tolerance, in which a graft is accepted without long-term immunosuppression, could overcome numerous obstacles in transplantation. Human allograft tolerance has been intentionally induced across HLA barriers via combined kidney and bone marrow transplantation (CKBMT) with a regimen that induces only transient chimerism. Tregs are enriched early after CKBMT. While deletional tolerance contributes to long-term tolerance, the role of Tregs remains unclear. We have optimized a method for identifying the donor-specific Treg repertoire and used it to interrogate the fate of donor-specific Tregs after CKBMT. We expanded Tregs with several different protocols. Using functional analyses and T cell receptor sequencing, we found that expanding sorted Tregs with activated donor B cells identified the broadest Treg repertoire with the greatest potency and donor specificity of suppression. This method outperformed both alloantigen stimulation with CTLA4Ig and sequencing of CFSE lo cells from the primary mixed lymphocyte reaction. In 3 tolerant and 1 nontolerant CKBMT recipients, we sequenced donor-specific Tregs before transplant and tracked them after transplant. Preexisting donor-specific Tregs were expanded at 6 months after CKBMT in tolerant patients and were reduced in the nontolerant patient. These results suggest that early expansion of donor-specific Tregs is involved in tolerance induction following CKBMT.